Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2021

View Archived Issues

Bright Minds Biosciences compound reduces seizures in animal models of Dravet syndrome/epilepsy

Persica completes first stage of clinical trial on PP-353 for low back pain

Vigil Neuroscience advances TREM2 agonists

CAR T-cell therapy enters first-in-human trial for hematologic cancers

Esteve Pharmaceuticals presents new analgesic drugs

Children's Medical Center patents ALK CAR for melanoma and neuroblastoma

LP-184 induces tumor growth inhibition in glioblastoma models

Vyant Bio to collaborate with Cyclica on discovery of treatments for CDKL5 deficiency disorder

Fate Therapeutics details responses seen in trials of FT-516 and FT-596

Phase II data show improvements in GM2 gangliosidosis with IB-1001

IBI-362 demonstrates body weight-lowering effect in phase I trial

Coeptis Therapeutics and VyGen-Bio to codevelop products targeting CD38 cancers

AAV9 gene therapy enters clinical development for Canavan disease

CRISPR Therapeutics AG presents new CAR Tcells for immuno-oncology

Rare gene variants increase zoonotic H7N9 susceptibility

[11C]MTP-38 first use in human PET studies shows promise for neurological disorders

VEGFC mRNA-LNP platform induces formation of a functional lymphatic network and reverses lymphedema

IL-26 is involved in malignant pleural effusion and associated with poor prognosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...